23-Mar-2026 5:55 PM CST - Morningstar Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. Under the terms of the deal, Gilead would buy all of the outstanding equity of Ouro for about $1.68 billion in cash upfront, which is payable at closing, and up to $500 million in contingent milestone payments.
19-Mar-2026 8:04 AM CST - Yahoo Finance A Look At Gilead Sciences (GILD) Valuation As Recent Returns Send Mixed Signals With no single news headline setting the tone, Gilead Sciences (GILD) has still given investors plenty to think about, as the share price and fundamentals paint a mixed, data rich picture. Over the past month the stock shows a return of about a 9% decline,
18-Mar-2026 6:05 AM CST - Yahoo Finance 3 Reasons to Avoid GILD and 1 Stock to Buy Instead Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead Sciences has surged 127% to $145.23 per share.
3-Mar-2026 1:57 AM CST - Yahoo Finance Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance Gilead Sciences has entered a definitive agreement to acquire Arcellx, Inc. in a cash deal valued at $7.8b. The transaction expands Gilead's presence in oncology and cell therapy, areas that differ from its core HIV franchise.
23-Feb-2026 3:05 PM CST - Business Wire Gilead Sciences to Present at Upcoming Investor Conferences #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 3 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 11:20 AM Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 11 at 11:00 AM Eastern Time The live webcasts can be accessed at the companys investors pa
23-Feb-2026 4:30 AM CST - Seeking Alpha Gilead Sciences to buy Arcellx in deal worth up to $7.8B Gilead Sciences ( GILD) has agreed to acquire biotechnology company Arcellx ( ACLX) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an implied equity value of $7.8B payable at closing.
18-Feb-2026 7:45 AM CST - Benzinga Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.59%. Currently, Gilead Sciences has a market capitalization of $192.
Latest GILD Trades by Congress Members
27-JAN-2026 - Josh Gottheimer, NJ (District 5) purchased between $1,001 and $15,000.
23-Mar-2026 5:55 PM CST - Morningstar Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. Under the terms of the deal, Gilead would buy all of the outstanding equity of Ouro for about $1.68 billion in cash upfront, which is payable at closing, and up to $500 million in contingent milestone payments.
19-Mar-2026 8:04 AM CST - Yahoo Finance A Look At Gilead Sciences (GILD) Valuation As Recent Returns Send Mixed Signals With no single news headline setting the tone, Gilead Sciences (GILD) has still given investors plenty to think about, as the share price and fundamentals paint a mixed, data rich picture. Over the past month the stock shows a return of about a 9% decline,
18-Mar-2026 6:05 AM CST - Yahoo Finance 3 Reasons to Avoid GILD and 1 Stock to Buy Instead Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead Sciences has surged 127% to $145.23 per share.
3-Mar-2026 1:57 AM CST - Yahoo Finance Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance Gilead Sciences has entered a definitive agreement to acquire Arcellx, Inc. in a cash deal valued at $7.8b. The transaction expands Gilead's presence in oncology and cell therapy, areas that differ from its core HIV franchise.
23-Feb-2026 3:05 PM CST - Business Wire Gilead Sciences to Present at Upcoming Investor Conferences #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 3 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 11:20 AM Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 11 at 11:00 AM Eastern Time The live webcasts can be accessed at the companys investors pa
23-Feb-2026 4:30 AM CST - Seeking Alpha Gilead Sciences to buy Arcellx in deal worth up to $7.8B Gilead Sciences ( GILD) has agreed to acquire biotechnology company Arcellx ( ACLX) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an implied equity value of $7.8B payable at closing.
18-Feb-2026 7:45 AM CST - Benzinga Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.59%. Currently, Gilead Sciences has a market capitalization of $192.
